Business Wire

LR-HEALTH-&-BEAUTY

Share
Review 2016: LR Health & Beauty Continues Successful Course

The positive trend from 2015 continues: LR Health & Beauty was able to expand its positive business development in 2016. The Ahlen-based network marketing company recorded sales of nearly EUR 258 million, up 15 percent on a year-on-year basis (net of currency effects). Key growth drivers in turnover were the international markets such as Turkey, Italy, Poland, Belgium, the Netherlands and Spain with double-digit growth. But in Germany as well, LR grew by almost 20 percent in the acquisition of new sales partners, thus laying the foundation for sustainable success. "This is an excellent development that confirms the confidence in our business model," says Dr. Thomas Stoffmehl, CEO of LR Health & Beauty and spokesman of the Management Board.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170301005091/en/

In focus for 2017: Support of sales partners

The targeted support of the sales partners, the development of careers and, as a result, the sustained expansion of sales structures take centre stage in 2017. "As a genuine network marketing company, the intensive exchange and dialogue with our sales partners is essential for us. This is the only way to ensure that the sales partners are supported in a needs-oriented way, to win them over to our business and bind them in the long term,” says Dr. Thomas Stoffmehl.

Site investment: Extension of the production capacities

The expansion of the company site in Ahlen is part of the company's sustainable growth strategy. A production site for the Aloe Vera Drinking gels is being built there and will be completed by the end of 2017. With a turnover of 39%, the Aloe Vera product segment is one of the most important core competencies of LR. With an annual harvesting volume of 12,000 tonnes of aloe vera leaves, the company is among the world’s largest manufacturers of aloe vera products. The production plant will be state-of-the-art and closely interlinked with logistics. LR thus strengthens its claim "Made in Germany" with the highest quality standards.

The direct selling industry faces challenges over the next years. “In the age of digitalisation, it is important to modernise the business model, continuously expand a first-class, innovative product portfolio and build up a motivated partner organisation to remain well-positioned for a promising future. With a strong team of over 1,200 LR employees worldwide, we are well positioned to tackle these challenges,” says Dr. Thomas Stoffmehl.

LR Health & Beauty

Under the motto “More quality for your life“, the LR Group with headquarters in Ahlen/Westphalia produces and markets various health and beauty products in around 28 countries. The range includes care and decorative cosmetics, dietary supplements and perfumes. In the fragrance segment, the company, which was in founded in 1985, has established exclusive cooperations with celebrities such as Guido Maria Kretschmer, Karolina Kurkova and Bruce Willis. With more than 1,200 employees as well as thousands of registered sales partners and customers, LR is one of Europe’s leading direct sales enterprises. Since 2014, LR products are also available at the company's customer online shop. LR's strong market position is based above all on a high-quality product range and an attractive bonus and training plan which is unsurpassed in the industry. LR also established the LR Global Kids Fund e. V. which provides efficient and unbureaucratic support for deprived children and their families in many different countries around the world in cooperation with local institutions.

Contact:

LR Health & Beauty
Almut Kellermeyer
Head of PR / Public Affairs
Tel: +49 2382 70 60 114
Email: a.kellermeyer@LRworld.com
or
impact Agentur für Kommunikation GmbH
Mieke Meimbresse
Tel. + 49 69 955264-33
Email: m.meimbresse@impact.ag

Link:

ClickThru

Social Media:

https://www.facebook.com/lrworld.de

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

Illumynt Reports Q3 2025 Business Update17.10.2025 14:39:00 CEST | Press release

Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye